Antiva Biosciences
PrivateLast Round
Series E
Apr 27, 2023
Total Funding Raised
$141.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Antiva Biosciences is a biotechnology company that develops small molecule antivirals aimed at enhancing health outcomes for patients affected by HPV and other viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antiva Biosciences Comparables
Compare Antiva Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Frantz Viral Therapeutics | 82% | |
| Amplexd Therapeutics | 76% | |
| Asieris Pharmaceuticals | 73% |
Antiva Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Apr 27, 2023 | ||||
| Series D | Nov 2, 2021 | ||||
| Series C Extension | Jul 10, 2018 | ||||
| Series C | Mar 28, 2017 | ||||
| Series B | Aug 6, 2015 | ||||
Series A | Jul 1, 2014 |
Antiva Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series C Extension, Series D |
| Brace Pharma Capital | Series C, Series C Extension, Series D |
| GV | Series E, Series D |
| Hillhouse Investment | Series C Extension |
| Gaingels | Series D |
| Mana Ventures | Series D |
| Avestria Ventures | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 70% MoM.
- May 15, 2026
Monthly visitors grew 530% MoM, reaching 1.8K.
Antiva Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antiva Biosciences's valuation, stock price, and market status.
Is Antiva Biosciences a public or private company?
Antiva Biosciences is a private company.
What is the current stock price of Antiva Biosciences?
Antiva Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Antiva Biosciences worth (valuation)?
Valuation information for Antiva Biosciences is not publicly available.
Can I buy Antiva Biosciences stock?
Antiva Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Antiva Biosciences's last funding round?
Antiva Biosciences's most recent funding round was Series E on April 27, 2023.
Who are the main investors in Antiva Biosciences?
Key investors in Antiva Biosciences include Brace Pharma Capital, GV, Hillhouse Investment, MPM BioImpact, Canaan Partners.
Will Antiva Biosciences IPO soon?
No public IPO plans have been announced for Antiva Biosciences.
How can I track Antiva Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Antiva Biosciences's secondary market activity and sign up for updates.